Actively Recruiting

Phase 1
Phase 2
Age: 50Years - 75Years
All Genders
Healthy Volunteers
NCT05211986

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Led by Immunis, Inc. · Updated on 2025-10-30

28

Participants Needed

2

Research Sites

198 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis

CONDITIONS

Official Title

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Who Can Participate

Age: 50Years - 75Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Has moderate knee osteoarthritis (Kellgren-Lawrence grade 2 to 3) on the affected limb
  • Has quadriceps muscle weakness (less than 7.5 N/kg)
  • Can walk more than 50 feet without assistance
  • Has a body mass index (BMI) less than 40 kg/m2
  • Male participants agree to use contraception during treatment and for at least 3 months after last dose, and avoid sperm donation during this time
  • Female participants are not pregnant, not breastfeeding, and either not of childbearing potential or agree to use contraception during treatment and for at least 3 months after last dose
  • Female participants have a negative pregnancy test at screening and before treatment
  • Able to provide signed informed consent and comply with study requirements
  • Willing and able to follow all study procedures
  • Has stopped systemic oral or intravenous steroid use for at least 6 months before screening
  • Has vital signs within specified ranges at baseline: heart rate 51-99 bpm, systolic blood pressure 101-169 mmHg, diastolic blood pressure 51-89 mmHg, blood oxygenation over 95%
  • Has tried and failed at least one 3-month or longer treatment within 2 years before screening (such as activity modification, weight loss, physical therapy, anti-inflammatory meds, or injections)
  • Can speak, read, and understand English
Not Eligible

You will not qualify if you...

  • Has severe knee osteoarthritis (Kellgren-Lawrence grade above 3) on the opposite limb
  • Has had prior total knee replacement surgery
  • Known allergy to the study medication or related drugs/devices
  • Current or past malignancy within 5 years (except nonmelanoma skin cancer)
  • Neurological, vascular, or cardiac conditions limiting function or ability to participate
  • Uncontrolled comorbidities including diabetes (HbA1c over 7.0%), hypertension (heart rate over 100 bpm, systolic BP over 170 mmHg, diastolic BP over 90 mmHg), cardiovascular disease, asthma, or COPD
  • Positive for hepatitis B surface antigen, hepatitis C antibody, or HIV antibodies (negative RNA test for hepatitis C acceptable)
  • Taking or recently taken prohibited medications (narcotic pain meds, local anti-inflammatories, other investigational drugs)
  • Changed medication for comorbid conditions within 1 month before screening
  • Received intra-articular cortisone or viscosupplementation injections within 3 months before first dose
  • Received live attenuated vaccine within 28 days before starting treatment or expected during study
  • Current or chronic liver disease or known liver/biliary abnormalities (except Gilbert's syndrome or asymptomatic gallstones)
  • History of smoking within 10 years
  • History of chronic alcohol or drug abuse within past 3 months
  • Currently using systemic oral or intravenous steroids or brief pulse steroid course for chronic respiratory or other conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Orthopaedic Specialty Institute

Irvine, California, United States, 92618

Actively Recruiting

2

University of California, Irvine - Alpha Stem Cell Clinic

Orange, California, United States, 92868

Active, Not Recruiting

Loading map...

Research Team

J

Joelle Hafen, BS

CONTACT

E

Erin Curry, PA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here